ESR1 and cancer: While some ER + /HER2+ tumours behave more like the luminal A subtype (i.e., ER-driven cancer) and others as HER2-E tumour (HER2-driven cancer) or a combination of both which require a multipronged targeted blockade of both ER and HER2 pathways.